ACS NanoBioengineeringPeer-reviewed journal article
A High-Throughput Platform for Rapid Adaptation of DNA Aptamers to SARS-CoV-2 Evolution
Yujie HeiD, Zhenglin Yang, Yu-An Kuo, Yuting WuiD, Diego Fonseca-Albert, Kyle K Le, Jeffrey Guo, Yanxing WangiD, Anh-Thu Nguyen, Yuan‐I CheniD, Sohyun KimiD, Weiru CheniD, Saeed SeifiiD, Soonwoo HongiD, Trung Duc Nguyen, Yinong CheniD, Pengyu Y. ReniD, Yi LuiD, Hsin‐Chih YehiD
Abstract
Rapid pathogen evolution threatens public health by eroding the effectiveness of vaccines, therapeutics, and diagnostic tools. Although spike protein targeting monoclonal antibodies (mAbs) were developed within 10-12 months of the initial outbreak to serve as key theranostic agents, their redesign has struggled to keep pace with viral evolution, rendering many neutralizing antibodies ineffective. Here we demonstrate a novel platform that combines a random-rational hybrid library diversification with high-throughput MiSeq screening to rapidly reprogram aptamers against emerging SARS-CoV-2 spike variants. Interactions between 3 different spike proteins and 11,806 unique aptamer variant designs were profiled within a few days. Starting from a 40-nt aptamer originally selected against wild-type (WT) spike protein, our screen identified a Delta-binding mutant with a 4-fold affinity improvement and an Omicron-binding mutant that converted undetectable binding into nanomolar affinity. We also identified a WT-selective mutant with substantially reduced affinity for Delta, as well as previously unrecognized bases that critically contribute to spike recognition. Integrating high-throughput binding data with molecular dynamics simulations further revealed sequence-dependent structural features underlying variant-specific aptamer-spike interactions. Finally, we developed a sensor based on the identified WT-selective aptamer mutant, enabling highly specific detection of the WT spike protein with robust performance. Together, this work establishes a rapid and adaptable aptamer engineering platform for rapid adaptation of aptamers to evolving pathogens in future pandemics.
- organism: virus
- assay: DNA methylation
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 0
- FWCI
- 0.00
- Field percentile
- top 48%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Demonstration and structural basis of a therapeutic DNA aptamer for SARS-CoV-2 spike protein detection
Yujun Liu, Kaidong Wang, … Z. Hong Zhou·bioRxiv·Mar 14, 2025
- Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape
F. Zhao, C. Keating, … J. G. Jardine·bioRxiv·Jan 6, 2022
- Structural basis of SARS-Cov-2 spike recognition by engineered synthetic multivalent VHH antibodies
Ana González Hernández, Zane T. Laughlin, … Aaron K. Sato·bioRxiv·Oct 2, 2024
- High-Throughput, Single-Copy Sequencing Reveals SARS-CoV-2 Spike Variants Coincident with Mounting Humoral Immunity during Acute COVID-19
S. H. Ko, E. Bayat Mokhtari, … E. A. Boritz·bioRxiv·Feb 21, 2021
- High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses
Joshua J. Sims, Sharon Lian, … James M. Wilson·PLoS ONEPeer-reviewed·Aug 25, 2022
- Design of immunogens for eliciting antibody responses that may protect against SARS-CoV-2 variants
E. Wang, A. K. Chakraborty·bioRxiv·Jan 24, 2022